Search Videos by Topic or Participant
Browse by Series:

Final Thoughts on the Treatment of mCRC

Panelists Johanna Bendell, MD, Sarah Cannon; Marwan Fakih, MD, City of Hope; Heinz-Josef Lenz, MD, USC; John L. Marshall, MD, Georgetown; Alan
Published: Monday, Jul 07, 2014
For High-Definition, Click
In the final segment of the discussion, John Marshall, MD, asks the panelists to share their final thoughts on the treatment of metastatic colorectal cancer (mCRC). Johanna Bendell, MD, comments that expanded KRAS testing should be conducted in patients with mCRC. Also, patients with the BRAF mutation should be encouraged to enter clinical trials. Bendell further remarks that there are many agents in development; through patient participation in clinical trials, additional knowledge and experience will be gained regarding the treatment of mCRC.

The field is currently in the midst of a molecular revolution, notes Heinz-Josef Lenz, MD, and over time, more will be learned about patient selection for targeted treatments. Lenz adds that substantial progress will be made as advances in molecular biology are matched with appropriate targeted therapies.

There are many treatment options available and the treatment of mCRC is an art, comments Marwan Fakih, MD. It is important to discuss treatment goals with patients before initiating therapy, adds Fakih.

Alan Venook, MD, recommends a multidisciplinary approach, as opinions from other clinicians can be valuable when formulating a treatment plan. Venook further comments that it is important for patients to be offered enrollment in clinical trials, as the results of clinical trials will help address open questions regarding the treatment of mCRC.

Marshall wraps up the segment by commenting that there are many resources available for patients, including websites and advocacy groups, for example. He adds that it is important for clinicians to engage patients in discussions regarding enrollment in clinical trials.


Slider Left
Slider Right
For High-Definition, Click
In the final segment of the discussion, John Marshall, MD, asks the panelists to share their final thoughts on the treatment of metastatic colorectal cancer (mCRC). Johanna Bendell, MD, comments that expanded KRAS testing should be conducted in patients with mCRC. Also, patients with the BRAF mutation should be encouraged to enter clinical trials. Bendell further remarks that there are many agents in development; through patient participation in clinical trials, additional knowledge and experience will be gained regarding the treatment of mCRC.

The field is currently in the midst of a molecular revolution, notes Heinz-Josef Lenz, MD, and over time, more will be learned about patient selection for targeted treatments. Lenz adds that substantial progress will be made as advances in molecular biology are matched with appropriate targeted therapies.

There are many treatment options available and the treatment of mCRC is an art, comments Marwan Fakih, MD. It is important to discuss treatment goals with patients before initiating therapy, adds Fakih.

Alan Venook, MD, recommends a multidisciplinary approach, as opinions from other clinicians can be valuable when formulating a treatment plan. Venook further comments that it is important for patients to be offered enrollment in clinical trials, as the results of clinical trials will help address open questions regarding the treatment of mCRC.

Marshall wraps up the segment by commenting that there are many resources available for patients, including websites and advocacy groups, for example. He adds that it is important for clinicians to engage patients in discussions regarding enrollment in clinical trials.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x